RELATING TO INSURANCE -- INSURANCE COVERAGE FOR MENTAL ILLNESS AND, SUBSTANCE USE DISORDERS
Impact
If enacted, S2467 will amend existing laws concerning insurance coverage for mental illness and substance use disorders. By removing the requirement for preauthorization, the bill encourages faster access to needed care for patients, aligning insurance practices more closely with standard healthcare provisions. This change is expected to enhance treatment outcomes by allowing patients quicker entry into care processes, thus reducing the potential for exacerbated health conditions due to delayed treatment.
Summary
S2467 is a legislative measure aimed at improving access to mental health and substance use disorder services by prohibiting health insurance providers from requiring preauthorization for in-network services. This bill represents a significant effort to streamline the clinical care process, ensuring that individuals needing these critical services can receive timely treatment without unnecessary barriers. It addresses a growing concern regarding the accessibility of mental health care and the stigmatization of individuals with substance use disorders.
Contention
The bill may face contention regarding the implications of removing preauthorization requirements. Supporters argue that it simplifies the process for patients and providers alike, allowing for more immediate care, while opponents may raise concerns over potential costs to insurers and the overall healthcare system. Additionally, questions may arise about the effectiveness of care management without prior authorization checks, which some believe can help to control costs and ensure appropriate use of services.
Authorizes emergency medical service agencies to transport individuals to alternative facilities for treatment and permits licensed providers for mental health disorders to treat patients within the community.
Mandates all insurance contracts, plans or policies provide insurance coverage for the expense of diagnosing and treating infertility, for women between the ages of 25 and 42 years including preimplantation genetic diagnosis (PGD) in conjunction with IVF.
Residential Substance Use Disorder Treatment Act of 2023 This bill revises and reauthorizes through FY2027 grants for residential substance use disorder treatment programs at state and local correctional and detention facilities. Among the revisions, the bill replaces statutory references to substance abuse with substance use disorder, specifies that the term residential substance use disorder treatment program includes a medication-assisted treatment program, requires the chief medical officer or other staff overseeing a program to complete training on the science of addiction and the latest research and clinical guidance on treating substance use disorders in criminal justice settings, and allows people who are awaiting trial or in pretrial detention to participate in the programs.
Requiring licensure of outpatient substance use disorder treatment facilities and relative to complaint investigation of treatment facilities by the department of health and human services office of the ombudsman and making an appropriation therefor.
Establishing the Nonnarcotic Medication Substance Use Disorder Treatment Program; in organization and jurisdiction of courts of common pleas, providing for court assessments for substance use disorder treatment; in other criminal provisions, further providing for supervisory relationship to offenders; and, in Pennsylvania Board of Probation and Parole, further providing for supervisory relationship to offenders.